Vioxx

Readers of this blog are, by now, aware of the many issues surrounding Merck’s blockbuster nonsteroidal, anti-inflammatory medication Vioxx (rofecoxib) and negative cardiac events. The cardiac problems associated with Vioxx, and its subsequent withdrawal from the market, spawned scores of lawsuits. These include Merck shareholder lawsuits, which were recently the subject of oral [...]  

WHITEHOUSE STATION, N.J., Merck today presented oral arguments in the U.S. Supreme Court in Merck & Co., Inc., v. Richard Reynolds. - - The Supreme Court is reviewing a decision reinstating a securitie...  

WASHINGTON (AP) — Lawyers for Merck & Co. have told the Supreme Court that investors waited too long to sue over its warnings about the risks of its former blockbuster painkiller Vioxx before it was pulled from the market. Merck wants the high court to throw out an investors' class-action securities lawsuit. They sued because of the tens of billions of dollars in shareholder value lost overnight after Merck pulled Vioxx off the...  

"Some Justices Voice Skepticism of Merck in Vioxx Case": Brent Kendall of Dow Jones Newswires has this report. And law.com's Tony Mauro reports that "High Court Seems Unconvinced by Merck in Vioxx Arguments."...  

Merck (MRK) got a rough ride at the U.S. Supreme Court on Monday. The justices ridiculing the company’s argument that investors in its stock should have sued the company earlier over its misrepresentations about Vioxx even though they would not have had the evidence for their suits to succeed at that time.  

By ASSOCIATED PRESS ASSOCIATED PRESS Lawyers for Merck & Co. told the Supreme Court on Monday that investors waited too long and didn't do all of the necessary investigations to sue the drug maker...  

Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market, according to new data.  

A new report published in the Archives of Internal Medicine has found that drugmaker Merck knew about the increased cardiovascular risks of its arthritis drug Vioxx years before the company voluntarily recalled the medicine.  

We have long been writing about the links between Merck’s blockbuster nonsteroidal, anti-inflammatory medication Vioxx (rofecoxib) and negative cardiac events. Now, according to Science Daily, a study has found that evidence of cardiovascular risks linked to Vioxx might have been realized almost four years before Merck & Co. Inc., pulled the drug from the market. Vioxx [...]  

Boston (DbTechNo) - It appears that heart risks associated with Vioxx were known about up to 3 years before Merck pulled their drug from the market. The painkiller was pulled from the market back in 2004, after it became apparent that the drug had severe heart attack risk in patients who received it. This news comes from [...]  

Before the headlines hit about the dangers of using Vioxx (rofecoxib), researchers were already aware, say news reports. Vioxx, a non-steroidal anti-inflammatory (NSAID), was made by Merck & Co. Inc., and introduced to the American market in 1999. The company then voluntarily pulled the drug from the market in September 2004, after there were multiple reports of increased risk of heart attack and stroke associated with long-term, high-dose use...  

Birmingham StarOn Merck's Interesting Supreme Court ArgumentWall Street Journal (blog)Williams & Connolly's Kannon Shanmugam is, by many accounts, a rising star of the Supreme Court bar. As an assistant to the Solicitor General ...'Nothing is more important than patient safety'Irish TimesSome Justices Voice Skepticism of Merck in Vioxx CaseWall Street Journalall 201 news articles »  

CHICAGO (Reuters) - Heart risks from taking Merck & Co Inc's painkiller Vioxx could have been detected more than three years before the company withdrew the drug from the market in September 2004, had the data been openly available, U.S. researchers said on Monday.  

Der US-Pharmakonzern Merck & Co. hat im Fall um das Schmerzmittel Vioxx eine juristische Niederlage in Deutschland erlitten. Das Oberlandesgericht Brandenburg verpflichtete die deutsche Merck-Tochter MSD Sharp & Dohme nach Informationen des Berliner "Tagesspiegel" (Freitagausgabe) dazu, alle internen Unterlagen über Nebenwirkungen des Schmerzmittels herauszugeben. Das Blatt beruft sich auf das Gericht. Nach Berichten über ein möglicherweise...  

You’d think that after the Vioxx fiasco, Merck might be a little more careful about pushing drugs that don’t offer much benefit. Well, if you did think that, you’d be wrong. A new study in the New England Journal of Medicine this week shows that two very, very profitable cholesterol drugs are pretty much useless. Merck has been at least partly aware of this for 3 years, but they still don't want to admit it – not surprising given that sales...